April I 2025

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.

Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: trifluridine/tipiracil and regorafenib.

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management during the 2024 US Prostate Cancer Conference.

Rapid breast cancer research offers new hope, as discussed by Joyce O’Shaughnessy, MD, regarding HR+/HER2– and HER2+ disease.

The AERIAL trial will assess LEU011, which has MHRA Innovation Passport status, for solid tumors, a challenging area compared with hematologic cancers.

Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly delineated, even in phase 3 trials.

John M. Burke, MD, highlights findings from the AQUILA, DREAMM 7, and MajesTEC-5 trials in multiple myeloma.